

1P-714-C025

## Monoclonal Antibody to CD105 (mouse) Phycoerythrin (PE) conjugated (0.025 mg)

Clone: MJ7/18

Isotype: Rat IgG2a

**Specificity:** The rat monoclonal antibody MJ7/18 reacts with CD105 (Endoglin), a 90 kDa type I

homodimerizing membrane glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow

and erythroid precursors in fetal and adult bone marrow.

Regulatory Status: RUO

Immunogen: Inflamed mouse skin

Species Reactivity: Mouse

**Preparation:** The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum

conditions. The conjugate is purified by size-exclusion chromatography.

Concentration: 0.5 mg/ml

Storage Buffer: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

**Usage:** The reagent is designed for Flow Cytometry analysis.

Expiration: See vial label

Lot Number: See vial label

Background: CD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in

presence of TGFbetaR-2 as a receptor for TGFbeta-1 and TGFbeta-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonises the inhibitory effects of TGFbeta-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of

new blood vessels.



## PRODUCT DATA SHEET

## References:

\*Rosu-Myles M, She YM, Fair J, Muradia G, Mehic J, Menendez P, Prasad SS, Cyr TD: Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells. PLoS One. 2012;7(6):e38954. doi: 10.1371/journal.pone.0038954.

\*Cho SK, Bourdeau A, Letarte M, Zúñiga-Pflücker JC: Expression and function of CD105 during the onset of hematopoiesis from Flk1(+) precursors. Blood. 2001 Dec 15;98(13):3635-42.

\*Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res. 2005 May-Jun;25(3B):1851-64.

\*Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M: Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res. 2010 Apr 1;86(1):12-9. doi: 10.1093/cvr/cvp332.

\*Herouet C, Cottin M, LeClaire J, Enk A, Rousset F: Contact sensitizers specifically increase MHC class II expression on murine immature dendritic cells. In Vitr Mol Toxicol. 2000 Summer;13(2):113-23.

\*Dassler K, Roohi F, Lohrke J, Ide A, Remmele S, Hütter J, Pietsch H, Pison U, Schütz G: Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105-specific iron oxide nanoparticles. Invest Radiol. 2012 Jul;47(7):383-91

\*Ge AZ, Butcher EC: Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-beta ligand. Gene. 1994 Jan 28;138(1-2):201-6.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.